BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
40.225 EUR
+0.64 (+1.62%)
Overall BRM gets a fundamental rating of 6 out of 10. We evaluated BRM against 55 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on BRM. Finally BRM also has an excellent dividend rating. These ratings would make BRM suitable for value and dividend investing!
1. Profitability
1.1 Basic Checks
In the past year BRM was profitable.
BRM had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BRM reported negative net income in multiple years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BRM's Return On Assets of 6.23% is in line compared to the rest of the industry. BRM outperforms 55.36% of its industry peers.
BRM has a better Return On Equity (32.55%) than 82.14% of its industry peers.
With an excellent Return On Invested Capital value of 16.42%, BRM belongs to the best of the industry, outperforming 80.36% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 14.51%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(16.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
BRM has a Profit Margin (12.57%) which is in line with its industry peers.
BRM has a Operating Margin of 33.51%. This is amongst the best in the industry. BRM outperforms 83.93% of its industry peers.
In the last couple of years the Operating Margin of BRM has declined.
BRM's Gross Margin of 73.15% is in line compared to the rest of the industry. BRM outperforms 58.93% of its industry peers.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BRM is creating value.
Compared to 1 year ago, BRM has less shares outstanding
The number of shares outstanding for BRM has been reduced compared to 5 years ago.
BRM has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.11 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.11, BRM is doing worse than 60.71% of the companies in the same industry.
The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.20, BRM is doing good in the industry, outperforming 60.71% of the companies in the same industry.
BRM has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.41, BRM is doing worse than 82.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.11 |
ROIC/WACC2.1
WACC7.82%
2.3 Liquidity
BRM has a Current Ratio of 1.27. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.27, BRM is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
A Quick Ratio of 1.17 indicates that BRM should not have too much problems paying its short term obligations.
The Quick ratio of BRM (1.17) is better than 66.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 460.68%, which is quite impressive.
The earnings per share for BRM have been decreasing by -24.57% on average. This is quite bad
Looking at the last year, BRM shows a small growth in Revenue. The Revenue has grown by 1.26% in the last year.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
Based on estimates for the next years, BRM will show a very strong growth in Earnings Per Share. The EPS will grow by 35.26% on average per year.
The Revenue is expected to decrease by -5.17% on average over the next years.
EPS Next Y472.54%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
EPS Next 5Y35.26%
Revenue Next Year-0.35%
Revenue Next 2Y-4.29%
Revenue Next 3Y-3.28%
Revenue Next 5Y-5.17%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 7.07 indicates a rather cheap valuation of BRM.
Based on the Price/Earnings ratio, BRM is valued cheaply inside the industry as 94.64% of the companies are valued more expensively.
BRM's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.45.
With a Price/Forward Earnings ratio of 7.61, the valuation of BRM can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 92.86% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of BRM to the average of the S&P500 Index (34.46), we can say BRM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.07 | ||
| Fwd PE | 7.61 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 94.64% of the companies listed in the same industry.
BRM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BRM is cheaper than 96.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.16 | ||
| EV/EBITDA | 5.99 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BRM's earnings are expected to grow with 73.23% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y131.12%
EPS Next 3Y73.23%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 5.40%, which is a nice return.
BRM's Dividend Yield is rather good when compared to the industry average which is at 2.96. BRM pays more dividend than 92.86% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.42, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.4% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
BRM pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP82.81%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
FRA:BRM (11/21/2025, 7:00:00 PM)
40.225
+0.64 (+1.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.84%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap81.88B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.88
Price Target45.93 (14.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.4% |
Yearly Dividend2.1
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)3.83%
PT rev (3m)1.63%
EPS NQ rev (1m)4.98%
EPS NQ rev (3m)4.45%
EPS NY rev (1m)0.81%
EPS NY rev (3m)-0.81%
Revenue NQ rev (1m)2.05%
Revenue NQ rev (3m)2.21%
Revenue NY rev (1m)0.74%
Revenue NY rev (3m)0.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.07 | ||
| Fwd PE | 7.61 | ||
| P/S | 1.96 | ||
| P/FCF | 6.16 | ||
| P/OCF | 5.67 | ||
| P/B | 5.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.99 |
EPS(TTM)5.69
EY14.15%
EPS(NY)5.29
Fwd EY13.14%
FCF(TTM)6.53
FCFY16.22%
OCF(TTM)7.09
OCFY17.62%
SpS20.49
BVpS7.91
TBVpS-10.09
PEG (NY)0.01
PEG (5Y)N/A
Graham Number31.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 16.42% | ||
| ROICexc | 21.58% | ||
| ROICexgc | 109.99% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.11 |
F-Score6
WACC7.82%
ROIC/WACC2.1
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y472.54%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year-0.35%
Revenue Next 2Y-4.29%
Revenue Next 3Y-3.28%
Revenue Next 5Y-5.17%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.82%
EBIT Next 3Y49.42%
EBIT Next 5Y23.49%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 10 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 472.54% in the next year.